Harvard Bioscience Expects Earnings Bump From Coulbourn Buy
Harvard Bioscience Inc. of Holliston said its acquisition of Coulbourn Instruments is expected to add $4 million in revenue to the company's earnings annually.
Harvard Bioscience is a developer of scientific instruments used in life sciences research and medicine. Coulbourn is a privately held manufacturer of measurement products used in laboratories to assess learning and memory.
The acquisition puts an established brand, expanded technical support, direct sales and distribution capabilities in Harvard Bioscience's portfolio.
For the second quarter, Harvard Bioscience reported a $1.9 million profit on $25.9 in revenue. A year earlier, the company's profit was $300,000 on revenue of $18 million.
Coulbourn is privately held and based in Pennsylvania.
WBJ Web Partners
Most Recent
Most Recent
0 Comments